亚盛医药(06855.HK) 公布，包销商已行使超额配股权及有关超额配股权之交割已于美国东部时间昨日(13日)进行，公司按照发售价为每股美国存托股份17.25美元(相当于每股相关股份约33.57港元)发行93.51万股美国存托股份，紧随有关超额配股权交割后约占已发行普通股的1.07%。
有关发售项下可选美国存托股份的所得款项总额约为1,613万美元(约1.26亿港元)，净额约为110万美元(约880万港元)，当中约5,000万至6,000万美元用于在中国寻求lisaftoclax用于治疗r/r CLL的NDA批准及于中国筹备商业化上市，推进lisaftoclax在美国及其他国家的临床开发；约3,000万至4,000万美元用于推进奥雷巴替尼在美国及其他国家的临床开发；约1,000万至2,000万美元用于资助其他候选产品的研发；余额用于开发未来的管线项目及作营运资金及一般公司用途。(jl/w)(港股报价延迟最少十五分钟。沽空资料截至 2025-02-13 16:25。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.